Anticoagulation Management Post-AF Ablation
This patient must continue oral anticoagulation indefinitely based on her CHA2DS2-VASc score, not on the success of her ablation procedure or current rhythm status. 1
Immediate Post-Ablation Period (Completed)
At 4 weeks post-ablation, this patient has already completed the mandatory minimum 2-month anticoagulation period required for all patients after AF ablation, regardless of rhythm outcome or stroke risk score 1. This universal requirement prevents peri-procedural thromboembolism during the healing phase.
Long-Term Anticoagulation Decision
The critical determination now is whether to continue anticoagulation beyond the initial post-ablation period. The 2024 ESC guidelines are explicit: continuation of oral anticoagulation after AF ablation must be based on the patient's CHA2DS2-VASc score, NOT on the perceived success of the ablation procedure 1.
Calculate CHA2DS2-VASc Score
For this 74-year-old woman:
- Age 74 years = 1 point (age 65-74)
- Female sex = 1 point
- Total minimum score = 2 points
With a CHA2DS2-VASc score ≥2 in women, long-term anticoagulation is required independent of the ablation success 1, 2.
Recommended Anticoagulation Regimen
A direct oral anticoagulant (DOAC) is the preferred agent over warfarin for eligible patients to mitigate bleeding risk while preventing thromboembolism 1.
Appropriate DOAC options include:
- Apixaban 5 mg twice daily (or 2.5 mg twice daily if dose-reduction criteria met)
- Rivaroxaban 20 mg once daily (or 15 mg if CrCl 30-49 mL/min)
- Edoxaban 60 mg once daily (or 30 mg if dose-reduction criteria met)
- Dabigatran 150 mg twice daily (or 110 mg twice daily in selected patients)
Critical Clinical Pitfall
The most common error is discontinuing anticoagulation after successful ablation with maintained sinus rhythm. The evidence is clear that rhythm status post-ablation does not predict stroke risk—the underlying stroke risk factors (captured in CHA2DS2-VASc) persist regardless of whether AF recurs or is detected 1. Even patients with apparent "cure" from ablation retain their baseline thromboembolic risk.
Monitoring Considerations
While this patient is currently in normal sinus rhythm with normal ECG parameters (PR 144 ms, QRS 100 ms, QTc 442-460 ms, HR 65 bpm), these findings do not change anticoagulation decisions. Subclinical AF recurrence may occur without symptoms, further supporting the guideline recommendation to base anticoagulation on stroke risk scores rather than rhythm monitoring outcomes.